Afra Ishtiaque, Shahreen Mehmood Khan, S. Azhar, M. Mehmood, Saira Shahnawaz
{"title":"达格列净二甲双胍与西格列汀二甲双胍治疗新诊断2型糖尿病的疗效比较","authors":"Afra Ishtiaque, Shahreen Mehmood Khan, S. Azhar, M. Mehmood, Saira Shahnawaz","doi":"10.53350/pjmhs221610459","DOIUrl":null,"url":null,"abstract":"Objective: To comparison of the efficacy of dapagliflozin+metformin versus sitagliptin+metformin: in newly diagnosed type 2 diabetes Methodology: In this Randomized Control Trial, we enrolled a total of 180 cases; 90 cases newly diagnosed type 2 diabetes mellitus (HbA1c>6.5) in two equal groups A&B on the basis of computer-generated randomization table. Group A was allotted to the cases 100mg q.d sitagliptin plus 850 mg in addition to 500mg metformin 2 times a day. Patients of Group B were advised for 10mg qd dapagliflozin+500mg metformin 2 times a day for six months. Patients were followed up on monthly basis for any inconvenience. The final follow-up was done on 6th month of treatment. All the patients with poor/non-compliance were excluded from the study. All cases with HbA1c <6.0 were considered as effectively treated patients. Results: Comparison of Efficacy in both groups shows 44(48.9%) in Group A and 31(34.4%) in Group B, the overall efficacy was 41.7%, p-value=0.0.35 showing a significant difference. Conclusion: Dapagliflozin+metformin is significantly higher than sitagliptin+metformin for newly diagnosed type 2 diabetes Keywords: Newly type 2 diabetes, treatment, Dapagliflozin & Metformin Vs Sitagliptin & Metformin","PeriodicalId":296492,"journal":{"name":"Pakistan Journal of Medical & Health Sciences","volume":"39 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Comparison of the Efficacy of Dapagliflozin Metformin Versus Sitagliptin Metformin: in Newly Diagnosed Type 2 Diabetes\",\"authors\":\"Afra Ishtiaque, Shahreen Mehmood Khan, S. Azhar, M. Mehmood, Saira Shahnawaz\",\"doi\":\"10.53350/pjmhs221610459\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To comparison of the efficacy of dapagliflozin+metformin versus sitagliptin+metformin: in newly diagnosed type 2 diabetes Methodology: In this Randomized Control Trial, we enrolled a total of 180 cases; 90 cases newly diagnosed type 2 diabetes mellitus (HbA1c>6.5) in two equal groups A&B on the basis of computer-generated randomization table. Group A was allotted to the cases 100mg q.d sitagliptin plus 850 mg in addition to 500mg metformin 2 times a day. Patients of Group B were advised for 10mg qd dapagliflozin+500mg metformin 2 times a day for six months. Patients were followed up on monthly basis for any inconvenience. The final follow-up was done on 6th month of treatment. All the patients with poor/non-compliance were excluded from the study. All cases with HbA1c <6.0 were considered as effectively treated patients. Results: Comparison of Efficacy in both groups shows 44(48.9%) in Group A and 31(34.4%) in Group B, the overall efficacy was 41.7%, p-value=0.0.35 showing a significant difference. Conclusion: Dapagliflozin+metformin is significantly higher than sitagliptin+metformin for newly diagnosed type 2 diabetes Keywords: Newly type 2 diabetes, treatment, Dapagliflozin & Metformin Vs Sitagliptin & Metformin\",\"PeriodicalId\":296492,\"journal\":{\"name\":\"Pakistan Journal of Medical & Health Sciences\",\"volume\":\"39 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pakistan Journal of Medical & Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53350/pjmhs221610459\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Journal of Medical & Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53350/pjmhs221610459","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:比较达格列净+二甲双胍与西格列汀+二甲双胍治疗新诊断的2型糖尿病的疗效。方法:在这项随机对照试验中,我们共纳入180例;根据计算机生成的随机化表,将90例新诊断为2型糖尿病(HbA1c>6.5)的患者分为a、b两组。A组患者每日服用西格列汀100mg,外加850 mg,二甲双胍500mg,每日2次。B组患者给予达格列净10mg / d +二甲双胍500mg / d,每日2次,连用6个月。每月对患者进行随访,以防出现不便。最后一次随访于治疗第6个月进行。所有不良/不依从性的患者均被排除在研究之外。所有HbA1c <6.0的病例均视为有效治疗患者。结果:两组疗效比较:A组44例(48.9%),B组31例(34.4%),总疗效41.7%,p值=0.0.35,差异有统计学意义。结论:达格列净+二甲双胍治疗新诊断2型糖尿病的疗效显著高于西格列汀+二甲双胍。关键词:新诊断2型糖尿病,治疗,达格列净+二甲双胍Vs西格列汀+二甲双胍
A Comparison of the Efficacy of Dapagliflozin Metformin Versus Sitagliptin Metformin: in Newly Diagnosed Type 2 Diabetes
Objective: To comparison of the efficacy of dapagliflozin+metformin versus sitagliptin+metformin: in newly diagnosed type 2 diabetes Methodology: In this Randomized Control Trial, we enrolled a total of 180 cases; 90 cases newly diagnosed type 2 diabetes mellitus (HbA1c>6.5) in two equal groups A&B on the basis of computer-generated randomization table. Group A was allotted to the cases 100mg q.d sitagliptin plus 850 mg in addition to 500mg metformin 2 times a day. Patients of Group B were advised for 10mg qd dapagliflozin+500mg metformin 2 times a day for six months. Patients were followed up on monthly basis for any inconvenience. The final follow-up was done on 6th month of treatment. All the patients with poor/non-compliance were excluded from the study. All cases with HbA1c <6.0 were considered as effectively treated patients. Results: Comparison of Efficacy in both groups shows 44(48.9%) in Group A and 31(34.4%) in Group B, the overall efficacy was 41.7%, p-value=0.0.35 showing a significant difference. Conclusion: Dapagliflozin+metformin is significantly higher than sitagliptin+metformin for newly diagnosed type 2 diabetes Keywords: Newly type 2 diabetes, treatment, Dapagliflozin & Metformin Vs Sitagliptin & Metformin